As demand soared for weight-loss drugs, price signals worked.

Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill. Supreme Court declines to hear Trump donor's challenge to ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate ...

Medifast, Inc. faces declining demand amid GLP-1 impact, struggling repositioning efforts, and earnings uncertainty. Read ...

Although GLP-1 drugs have shown impressive results for weight loss, they are forcing employers to ask tough questions about whether to provide coverage. “It’s a complicated picture in terms of ...